Protalix BioTherapeutics, Inc. Stock TEL AVIV STOCK EXCHANGE
Equities
PLX
US74365A3095
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
732.5 ILa | -.--% | +3.29% | +69.68% |
Mar. 14 | Transcript : Protalix BioTherapeutics, Inc., 2023 Earnings Call, Mar 14, 2024 | |
Mar. 14 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 74.06M 27.88B | Sales 2025 * | 127M 47.94B | Capitalization | 87.66M 33B |
---|---|---|---|---|---|
Net income 2024 * | 17M 6.4B | Net income 2025 * | 70M 26.35B | EV / Sales 2024 * | 1.18 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.69 x |
P/E ratio 2024 * |
5.62
x | P/E ratio 2025 * |
1.46
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.23% |
Latest transcript on Protalix BioTherapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 19-06-29 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 19-07-21 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 20-07-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 19-11-30 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 19-11-30 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 14-10-31 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.13% | 42.11B | |
+48.83% | 40.08B | |
+8.49% | 40B | |
-10.82% | 26.87B | |
+8.26% | 24.58B | |
-23.69% | 18.44B | |
+1.58% | 11.94B | |
+32.83% | 11.66B | |
+6.63% | 11.01B |
- Stock Market
- Equities
- PLX Stock
- PLX Stock